DF
DFTX
DFTX What Definium Therapeutics promised, and what happened
Guidance
What management said, and what became of it
8 of 9 judged targets kept · 5 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Completion of enrollment in Voyage, Phase III GAD trial | conclude Voyage enrollment in the coming weeks (from 26 February 2026) | Dec 2025 | having completed enrollment in both Voyage and Panorama, our 2 Phase III studies in GAD | Achieved |
| Voyage Phase III GAD top-line data readout | top line Part A readout in the first half of 2026 | Jun 2024 | we anticipate presenting top line results from Voyage, our first Phase III study of DT120 ODT in generalized anxiety disorder, or GAD, during the week of August 10, 2026 | Missed |
| Cash runway — operations funded into 2027 and at least 12 months beyond the first Phase III GAD top-line readout | cash runway into 2027, at least 12 months beyond first Phase III GAD readout | Jun 2024 | we believe this capital is sufficient to fund planned operations into 2030 | Revised Up |
The full ledger
Open Definium Therapeutics’s full ledger
A free account opens 5 company ledgers a month. All 14 tracked commitments, with each call’s wording and source.
The rest of the ledger
Pro opens all 14 tracked commitments for Definium Therapeutics
Above is what the last two calls moved. Pro adds every quarter's revision, the source quote behind each one, and the topics management has stopped answering.